Showing results (121-130 of 165) with videos related to
Sort By:
Pageof 17
Leukemia & Lymphoma|August 14, 2025
Outcomes of relapsed/refractory peripheral T-cell lymphoma in the modern era: impact of stem cell transplant and novel agentsSeda S Tolu, Caitlin Gribbin, Zhengming Chen, et al.Hematology, Transfusion and Cell Therapy|November 19, 2021
Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. III: anti-CD19 CAR-T cell therapy for patients with non-Hodgkin lymphomaAlvaro J Alencar, Alexandre V Hirayama, Diego V Clé, et al.Leukemia & Lymphoma|June 7, 2026
Treatment intensity, illness burden, and disparities in newly diagnosed diffuse large B-cell lymphoma treated at an urban academic centerHua-Jay J Cherng, David DeStephano, Patrick Gould, et al.Blood Advances|September 9, 2022
Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphomaPamela B Allen, Xinyan Lu, Qing Chen, et al.European Journal of Haematology|April 22, 2026
Impact of Modern Strategies for Graft-Versus-Host Disease Prophylaxis on Relapse Risk in Matched-Sibling or Unrelated Donor Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis of Randomized TrialsLeonardo Javier Arcuri, Victor Hugo Glasser Natal, André Dias Américo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2011
Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL studyOwen A O'Connor, Barbara Pro, Lauren Pinter-Brown, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 2005
Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomasIssa F Khouri, Rima M Saliba, Chitra Hosing, et al.Clinical Lymphoma, Myeloma & Leukemia|January 2, 2013
Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trialJason R Westin, Michael A Thompson, Vince D Cataldo, et al.Blood|February 29, 2012
Phase 2 study of rituximab plus ABVD in patients with newly diagnosed classical Hodgkin lymphomaAnas Younes, Yasuhiro Oki, Peter McLaughlin, et al.British Journal of Haematology|August 12, 2015
Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphomaDai Chihara, Barbara Pro, Sanam Loghavi, et al.Pageof 17